跳至主要内容
临床试验/NCT06480578
NCT06480578
招募中
2 期

An Integrated Intervention Using a Pill Ingestible Sensor System to Trigger Actions on Multifaceted Social and Behavioral Determinants of Health Among PLWH

University of California, Los Angeles1 个研究点 分布在 1 个国家目标入组 110 人2024年12月19日

概览

阶段
2 期
干预措施
ISS-SBDOH arm
疾病 / 适应症
HIV/AIDS
发起方
University of California, Los Angeles
入组人数
110
试验地点
1
主要终点
Adherence to ART--percent of prescribed medication taken
状态
招募中
最后更新
2个月前

概览

简要总结

This study integrates technology-based adherence measures with alerts for social and behavioral determinants of health (SBDOH) to improve HIV treatment outcomes. It involves 110 adult patients from a Los Angeles County HIV clinic, focusing on those at risk for poor adherence. Participants will be randomized into intervention or usual care groups, with endpoints including intervention acceptability, SBDOH interventions, adherence to ART, viral load, and high-risk sexual activity. The study aims to assess the effectiveness of the integrated intervention in improving adherence, virologic outcomes, and reducing high-risk behavior among PLWH.

详细描述

Undetectable equals Untransmittable (U=U) reduces HIV stigma, empowers people living with HIV (PLWH), and has become a pillar in the goal of ending the HIV epidemic. Viral suppression eliminating risk of sexual HIV transmission emphasizes the importance of adherence to antiretroviral therapy (ART). Strategies to enhance adherence have typically not intervened in real-time and have focused on pill-taking reminders without interventions that address adverse social and behavioral determinants of health (SBDOH) associated with poor adherence and engagement in care. The complex multifactorial pathways of SBDOH, such as food insecurity, unstable housing, and substance use disorders, have led to inequities in achieving optimal adherence and sustained viral suppression. Los Angeles (LA) County, a hot spot for HIV infection and transmission, has been reported to have viral suppression rates of \~60%, well below the 95% target of Ending HIV Epidemic by 2030. Our team has an extensive track record of research on measurement of and interventions to enhance adherence to ART. The investigators have used novel technology-based adherence measures of ART developed in the past two decades, including the cutting-edge ingestible sensor (IS) technology to obtain non-inferred, real-time adherence monitoring by Proteus® Digital Health Feedback (PDHF) system. Despite its validation reported in our recent publications, the PDHF system has been limited by the lack of incorporation of SBDOH. For many years, a major focus in HIV clinics has been to have multidisciplinary teams of nurses, social workers, and case managers to address SBDOH; however, timing of interventions are often weeks to months after such problems have been identified. This study will develop and test an integrated intervention that combines IS technology and adverse SBDOH alerts to maximize adherence and viral suppression. Using real-time IS monitoring, our integrated intervention will be able to immediately trigger the existing multidisciplinary team at clinic to address SBDOH issues as soon as predefined patterns of poor adherence are observed. A cohort of 110 adult patients who have or are at high risk for sub-optimal adherence will be recruited from a LA County safety net HIV clinic, located in a geographic HIV hotspot, dealing many adverse SBDOH issues. Participants will be randomized into the intervention or usual care. The integrated intervention will run for 20 weeks, followed by a 10-week period to assess sustainability. The primary end points include acceptability of the integrated intervention, frequency and timeliness of SBDOH interventions, level of challenges of SBDOH in HIV treatment, and adherence to ART. The secondary end points include viral load, high-risk sexual activity defined by self-report, and detection of sexually transmitted infections. The overarching goals are to evaluate (i) acceptability of the integrated intervention, frequency and timeliness of SBDOH intervention, and level of challenges of SBDOH in HIV treatment; (ii) the efficacy of the integrated intervention for monitoring, facilitating, and improving adherence to ART; and (iii) the efficacy of the integrated intervention for improving virologic outcome and reducing high-risk sexual activity.

注册库
clinicaltrials.gov
开始日期
2024年12月19日
结束日期
2027年7月1日
最后更新
2个月前
研究类型
Interventional
研究设计
Parallel
性别
All

研究者

责任方
Principal Investigator
主要研究者

Honghu Liu

Professor

University of California, Los Angeles

入排标准

入选标准

  • HIV-infected individuals in HIV care
  • Greater than 17 years of age
  • Demonstrated ability to take co-encapsulated ARVs at the time of screening
  • Able to provide informed consent
  • Receiving ART with sub-optimal adherence estimated by patient (self-reports \< 90% adherence over last 28 days) or treating clinician \[e.g., based on gaps in treatment (e.g. missed appointments) or viral load elevations within 6 months\], or at high risk for sub-optimal adherence, or with known challenges with SBDOH (e.g. unstable housing, substance use disorder, and poverty
  • Currently receiving antiretroviral treatment that includes one of the following:
  • TDF/FTC (Truvada)
  • TAF/FTC (Descovy)
  • EFV/FTC/TDF (Atripla)
  • ABC/3TC (Epzicom)

排除标准

  • Inability to follow the study procedures manifested during the intake, as evidenced by mental confusion, disorganization, intoxication, withdrawal, risky or threatening behavior
  • Pregnancy (Evaluated during the screening visit through a pregnancy test.)

研究组 & 干预措施

ISS-SBDOH arm

Ingestion Sensor System (ISS) - Social and Behavioral Determinants of Health (SBDOH) arm

干预措施: ISS-SBDOH arm

Usual Care (UC) arm

Usual Care (UC) arm UC is chosen as the control condition because it meets ethical and moral requirements to attempt treatment.

结局指标

主要结局

Adherence to ART--percent of prescribed medication taken

时间窗: week 4, 8, 12, 16, and 20

Adherence to ART measured by ID(identification)-Cap system for up to 20 weeks, defined as percent of prescribed medication taken

Acceptability to the integrated intervention

时间窗: week 4, 8, 12, and 16

Acceptability to the integrated intervention will be evaluated by quantitative measures interviews. The items in the quantitative measure will be rated on five-item Likert scales ranging from very strongly disagree to very strongly agree. Domains to be assessed will include overall satisfaction (would recommend to friend, would use outside of study setting, satisfied with system), utility, and specific items such as helpfulness and convenience. In addition, the investigators will ask participants to rate items specific to the ID-Cap system (comfort of wristband, comfort receiving text messages).

Frequency and timeliness of SBDOH intervention, level of challenges of SBDOH in HIV treatment

时间窗: week 4, 8, 12, 16, 20, and 28

The investigators will collect SBDOH measures, such as economic stability (e.g., food security), health (e.g., gap in health coverage), neighborhood and built environment (e.g. transportation needs), social and community context (e.g., violence, and criminal justice involvement), and substance and alcohol use, sexual behavior, and other health related behaviors. Challenges of SBDOH will be measured as (i) the count of SBDOH issues one is facing, and (ii) the degree of each issue (e.g., low/medium/high with housing challenge) with summary scores. Frequency and timeliness of SBDOH intervention are measured as number of sessions, and time to first, and subsequent sessions, if applicable, from baseline, and others. This information will also be collected when intervention if triggered by the monitoring system.

Self-Reported Medication Adherence--percent of prescribed dose taken

时间窗: week 4, 8, 12, 16, 20, and 28

The investigators will use a widely used measure of percent of prescribed dose taken during the preceding seven days. This measure is easy to use and has been significantly associated with virological and immunological outcomes.

Patterns of dosing

时间窗: week 4, 8, 12, 16, 20, and 28

Patterns of dosing such as Patterns of consecutive missed doses in the past two weeks,

次要结局

  • Concentration of Plasma HIV viral load(baseline, week 4, 8, 12, 16, 20, and 28)
  • number of sexual partners(baseline, week 8, 16, and 28)
  • Number of condomless sex(baseline, week 8, 16, and 28)

研究点 (1)

Loading locations...

相似试验